|Cris Calsada||Chief Financial Officer|
|Jay Hagan||President and Chief Executive Officer|
|Denis Drygin||Chief Scientific Officer|
|Brian Cheng||Cantor Fitzgerald|
|Yi Chen||H.C. Wainwright|
Ladies and gentlemen thank you for standing by and welcome to the Regulus Therapeutics Q4 2021 Conference Call. [Operator Instructions] I’d now like to turn the conference over to your host, Cris Calsada.
You may begin.
Thank you operator. Good afternoon and thank you for joining us to discuss Regulus Therapeutics fourth quarter and full year 2021 financial results and corporate highlights.